Mylan Faces Patent Suit Over Generic Comtan

Law360, New York (January 25, 2011, 1:50 PM EST) -- Finnish pharmaceutical company Orion Corp. has filed a patent infringement suit against Mylan Pharmaceuticals Corp., seeking to block a generic version of Parkinson's disease drug Comtan.

Orion announced the filing of the suit in a statement Monday, several weeks after Orion was notified that Mylan had filed an abbreviated new drug application with the U.S. Food and Drug Administration to make a generic version of Comtan.

The active ingredient in Comtan, which is marketed in the U.S. exclusively by Novartis AG, is entacapone. The drug is...
To view the full article, register now.